Leronlimab with trifluridine plus tipiracil (TAS-102) and bevacizumab - (CLOVER)
- Indication
- CCR5+, microsatellite stable (MSS), relapsed or refractory metastatic colorectal cancer (mCRC)
- Stage
- phase2
- Event
- Conference Presentation
- Details
October 8, 2026: CytoDyn Inc. (OTCQB: CYDY) announced that updated clinical data from the ongoing Phase 2 CLOVER study (NCT06699836) of leronlimab in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab will be presented at the ESMO Congress 2026 in Madrid.
The study is evaluating the regimen in previously treated metastatic colorectal cancer (mCRC). The poster, titled “Leronlimab (LRM) in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) in metastatic colorectal cancer (mCRC): The phase 2 CLOVER study,” will be presented by Benjamin Weinberg, M.D., on October 25, 2026, from 12:00-12:45 p.m. CET. Poster ID is 820P, in Hall 5 at IFEMA Madrid.
The release describes this as an update from the company’s mCRC program and says the presentation will include additional clinical and translational insights. No efficacy or safety results were disclosed in the announcement. A copy of the poster is expected to be posted on CytoDyn’s website shortly after the presentation.
- Source
- View catalyst source ↗